Desogestrel-only contraception may reduce headache frequency and improve quality of life in women suffering from migraine

European Journal of Contraception and Reproductive Health Care

Volumn 18, Issue 5, 2013, Pages 394-400

  Merki Feld, Gabriele S ^a   Imthurn, Bruno ^a   Seifert, Burkhardt ^b   Merki, Laura L ^c   Agosti, Reto ^d   Gantenbein, Andreas R ^e  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ISPM   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d KLINIK HIRSLANDEN   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cerazette ; Desogestrel only contraception; Hormonal migraine; Menstrual migraine; MIDAS questionnaire; Progestogen only contraception

Indexed keywords

DESOGESTREL;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTRACEPTION; COUNSELING; DISABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; LEISURE; MIGRAINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADULT; CONTRACEPTIVES, ORAL, SYNTHETIC; DESOGESTREL; FEMALE; HEADACHE; HUMANS; LEISURE ACTIVITIES; MIDDLE AGED; MIGRAINE DISORDERS; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SICK LEAVE; YOUNG ADULT;

EID: 84884550051     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2013.814769     Document Type: Article

References (30)

1. Hagen K, Zwart J A, Vatten L, et a l. Prevalence of migraine and non-migrainous headache-head-HUNT, a large population-based study. Cephalalgia 2000; 20: 900-6.
2. Macgregor E A, Rosenberg J D, Kurth T. Sex-related differences in epidemiological and clinic-based headache studies. Headache 2011; 51: 843-59.
3. Peterlin B L, Gupta S, Ward T N, Macgregor A. Sex matters: Evaluating sex and gender in migraine and headache research. Headache 2011; 51: 839-42.
4. Macgregor EA. Menstrual migraine: A clinical review. J Fam Plann Reprod Health Care 2007; 33: 36-47.
5. Somerville B. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 1972; 22: 355-65.
6. Aegidius K, Zwart J A, Hagen K, et a l. Oral contraceptives and increased headache prevalence: The Head-HUNT Study. Neurology 2006; 66: 349-53.
7. Chang C L, Donaghy M, Poulter N. Migraine and stroke in young women: Case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ 1999; 318: 13-8.
8. Bigal M E, Kurth T, Santanello N, et a l. Migraine and cardiovascular disease: A population-based study. Neurology 2010; 74: 628-35.
9. Tzourio C, Tehindrazanarivelo A, Iglesias S, et al. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ 1995; 310: 830-3.
10. Schurks M, Buring JE, Kurth T. Migraine, migraine features, and cardiovascular disease. Headache 2010; 50: 1031-40.
11. Curtis K M, Mohllajee AP, Peterson H B. Use of combined oral contraceptives among women with migraine and nonmigrainous headaches: A systematic review. Contraception 2006; 73: 189-94.
12. Tzourio C, Iglesias S, Hubert JB, et al. Migraine and risk of ischaemic stroke: A case-control study. BMJ 1993; 307: 289-92.
13. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA 2000; 284: 72-8.
14. Lidegaard Ø, Lø kkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: National follow-up study. BMJ 2009; 339: b2890.
15. Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. Contraception 2001; 64: 295-9.
16. Rice C, Killick S, Hickling D, C oelingh Bennink H. Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum Reprod 1996; 11: 737-40.
17. Lipton R B, Stewart W F, Sawyer J, Edmeads J G. Clinical utility of an instrument assessing migraine disability: The Migraine Disability Assessment (MIDAS) questionnaire. Headache 2001; 41: 854-61.
18. Stewart W F, Lipton R B, Kolodner K B, et a l. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 2000; 88: 41-52.
19. Silberstein SD. Preventive migraine treatment. Neurol Clin 2009; 27: 429-43.
20. Tfelt-Hansen P, Olesen J. Taking the negative view of current migraine treatments: The unmet needs. CNS Drugs 2012; 26: 375-82.
21. Lidegaard Ø, Lø kkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366: 2257-66.
22. Schurks M, Rist PM, Bigal ME, et al. Migraine and cardiovascular disease: Systematic review and metaanalysis. BMJ 2009; 339: b3914.
23. Wober C, Brannath W, Schmidt K, et a l. Prospective analysis of factors related to migraine attacks: The PAMINA study. Cephalalgia 2007; 27: 304-14.
24. Nappi RE, Sances G, Allais G, et al. Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: A prospective diary-based pilot study. Contraception 2011; 83: 223-8.
25. Sulak P, Willis S, Kuehl T, et al. Headaches and oral contraceptives: Impact of eliminating the standard 7-day placebo interval. Headache 2007; 47: 27-37.
26. De Leo V, Scolaro V, Musacchio MC, et al. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril 2011; 96: 917-20.
27. Calhoun AH. Menstrual migraine: Update on pathophysiology and approach to therapy and management. Curr Treat Options Neurol 2012; 14: 1-14.
28. Calhoun A, Ford S, Pruitt A. The impact of extendedcycle vaginal ring contraception on migraine aura: A retrospective case series. Headache 2012; 52: 1246-53.
29. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343-9.
30. Hawkins K, Wang S, Rupnow M. Direct cost burden among insured US employees with migraine. Headache 2008; 48: 553-63.